Poor aqueous solubility and bioavailability are common challenges for oncology drugs, affecting up to 90% of new chemical entities (NCEs). Finding a scalable approach to solving these issues is critical to achieving clinical efficacy and taking a new drug to market.

Iterion Therapeutics, a clinical stage biotechnology company, is dedicated to developing novel cancer therapeutics for a broad range of cancers. When Iterion’s lead product, Tegavivint, demonstrated low solubility in water, they needed a partner who could not only solve their bioavailability challenges, but also develop a scalable formulation with a viable manufacturing strategy. They turned to the experts at Lubrizol Life Science Health (LLS Health).

In this case study, you’ll learn how LLS Health combined its nanomilling expertise and GMP manufacturing capabilities to maximize bioavailability, improve patient experience, and take Iterion’s poorly soluble compound into clinical studies. 

DOWNLOAD THE FULL CASE STUDY TO LEARN MORE >>>>>